Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000049.xml
Download PDF
Clin Colon Rectal Surg 2001; 14(2): 167-174
DOI: 10.1055/s-2001-15855
DOI: 10.1055/s-2001-15855
Medical Treatment of Crohn's Disease
Further Information
Publication History
Publication Date:
31 December 2001 (online)
ABSTRACT
Medical treatment of Crohn's disease has progressed from empiric pharmaceuticals to biological agents. These medications help induce and maintain remission, prevent postoperative recurrence, improve quality of life, and suppress intestinal inflammation. A multidisciplinary team composed of surgeons, physicians, enterostomal therapists, and dietitians optimizes therapy and helps to minimize complications.
KEYWORD
Crohn's disease - medical treatment - corticosteroids
REFERENCES
- 1 Azad Khan K A, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet . 1977; 2 892-895
- 2 Thomson A BR, Wright J P, Vatn M. Mesalazine (Mesasal/Claversal) 1.5 g b.d. versus placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther . 1995; 9 673-683
- 3 McLeod R S, Wolff B G, Steinhart A H. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology . 1995; 109 404-413
- 4 Camma C, Giunta M, Rosselli M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology . 1997; 113 1465-1473
- 5 Lochs H, Mayer M, Fleig W E. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI. Gastroenterology . 2000; 118 264-273
- 6 Summers R W, Swit D M, Session J T. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology . 1979; 77 847-869
- 7 Malchow H, Ewe K, Brandes J W, Goebell H, Ehms H. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology . 1984; 86 249-266
- 8 Singleton J W, Hanauer S B, Gitnick G L, Peppercorn M A, Robinson M G. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology . 1993; 104 1293-1301
- 9 Hanauer S B, Krawitt E L, Robinson M, Rick G G, Safdi M A. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Am J Gastroenterol . 1993; 88 1343-1351
- 10 Ursing B, Alm T, Barany F. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology . 1982; 83 550-562
- 11 Prantera C, Zannoni F, Scribano M L. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol . 1996; 91 328-332
- 12 Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology . 1995; 108 1617-1621
- 13 Colombel J F, Lemann M, Cassagnon M. GETAID: a controlled trial comparing ciprofloxacin and mesalazine for the treatment of active Crohn's disease. Gastroenterology . 1997; 112 A951
- 14 Giu G PH, Thomas P RS, Tizard M LV, Sanderson J D, Hermon-Taylor J. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother . 1997; 39 393-400
- 15 Summers R W, Switz D M, Sessions Jr T J. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology . 1979; 77 847-869
- 16 Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut . 1994; 35 360-362
- 17 Rutgeerts P, Lofberg R, Malchow H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med . 1994; 331 842-845
- 18 Feagan B, Greenberg G R, Lofberg R. Budesonide controlled release ileal release prolongs remission in Crohn's disease: a pooled analysis. Gastroenterology . 1997; 112 A970
- 19 Hellers G, Cortot A, Jewell D. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology . 1999; 116 294-300
- 20 Schoon E J, Blok B M, Geerling B J. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology . 2000; 119 1203-1208
- 21 Hanauer S, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol . 1997; 92 559-566
- 22 Present D, Korelitz B I, Wisch N. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized double blind study. N Engl J Med . 1980; 302 981-987
- 23 Markowitz J, Grancher K, Kohn N. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology . 2000; 119 895-902
- 24 Connell W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J L, Lennard-Jones J E. Safety of low-dose purine analogues in inflammatory bowel disease. Gastroenterology . 1994; 107 1905-1906
- 25 Lewis J D, Sanford Schwartz J, Lichtenstein G R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology . 2000; 118 1018-1024
- 26 Duchesne D, Latours S, Leclerc J M, Sallan S E, Theoret Y. Pharmacokinetics of oral and intravenous 6-mercaptopurine (6-MP) in childhood acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol . 1994; 13 A341
- 27 Otterness D, Szumlanski C, Lennard L. Human thiopurine methyl-transferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther . 1997; 62 60-73
- 28 Weinshilboum R M, Sladek S L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet . 1980; 32 651-662
- 29 Dubinsky M C, Lamothe S, Yang H Y. Optimizing and individualizing 6-MP therapy in IBD: the role of 6-MP metabolite levels and TPMT genotyping. Gastroenterology . 1990; 116 A702
- 30 Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut . 1996; 39 401-406
- 31 Cuffari C, Picco M, Hunt S. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology . 1999; 116 A694
- 32 Dubinsky M C, Lamothe S, Yang H Y. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology . 2000; 118 705-713
- 33 Achkar J P, Stevens T, Brzezinski A. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy (abstract). Am J Gastroenterol . 2000; 96 2491
- 34 Feagan B G, Rochon J, Fedorak R N. Methotrexate for the treatment of Crohn's disease. N Engl J Med . 1995; 332 292-297
- 35 Feagan B G, Fedorak R N, Irvine E J. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med . 2000; 342 1627-1632
- 36 Van Dullemen M H, Van Deventer J H S, Hommes D W, Bijl H A, Jansen J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology . 1995; 109 129-135
- 37 Targan S R, Hanauer S B, Sander H H. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med . 1997; 337 1029-1035
- 38 Present D H, Rutgeerts P, Targan S. Infliximab treatment of fistulas in patients with Crohn's disease. N Engl J Med . 1999; 340 1398-1405
- 39 Rutgeerts P, D'Haens G, Targan S. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology . 1999; 117 761-769
- 40 Hanauer S B, Cohen R D, Becker R V. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther . 1998; 20 1009-1028
- 41 Mate J, Castanos R, Garcia-Samaniego J, Pajares J M. Does dietary fish oil maintain remission of Crohn's disease: a study case control. Gastroenterology . 1991; 100 A228
- 42 Beluzzi A, Brignola C, Campieri M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med . 1996; 334 1557-1560
- 43 Gonzalez-Huix F, de Leon R, Fernandez-Banares F. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut . 1993; 34 778-782
- 44 Sampaio E P, Kaplan G, Miranda A. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis . 1993; 168 408-414
- 45 Ehrenpreis E D, Kane S K, Cohen L B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology . 1999; 117 1271-1277
- 46 Vasiliauskas E A, Kam L Y, Abreu-Martin M T. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology . 1999; 117 1278-1287
- 47 Zeldis J B, Williams B A, Thomas S D. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther . 1999; 21 319-330